Last article about Optina:
Tuesday, October 8, 2013 09:00 AM
"the immediate initiation of an open label extension study using this optimum dose of Optina for all patients who have completed the trial and wish to continue treatment for an additional 12 weeks"
The "additional 12 weeks" was finisihed last week, so we can hear about optina result next week
That may be optimistic. The same news release stated "At least thirty percent (30%) of patients had reached the first 4 week time point" for the interim analysis. So, only those patients (number unknown) that had completed the trial at that time would have completed the extension study at this time.
Then again,per stock action, something might be up, or perhaps one of the fund managers at the last investment meeting are allocating 2014 capital now.
I sure hope so. That may be pretty quick to analyze the results to the point of being able announce anything. If they announce that they look good without details, a number of "short" [- sighted] people will slam it, as is par for the course. However, this could give the boost to $12+.